AAA Ramps Up Lutathera Launch And Plans Expansion Under Novartis Ownership

Novartis AG completed the $3.9bn acquisition of nuclear medicine specialist Advanced Accelerator Applications (AAA) in January, just four days before the company's first drug, Lutathera (lutetium Lu 177 dotatate), was approved by FDA for a rare, complex cancer. Now the company is ramping up the launch of Lutathera, a peptide receptor radionuclide therapy, while preparing to expand the technology platform to a broader range of tumors.

AAA President Susanne Schaffert talked to Scrip last month at the American Society of Clinical Oncology (ASCO) meeting about the launch, AAA's expansion strategy under the ownership of